| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
HYDRIDE-L does not have a biological target; it is a synthetic intermediate used in the synthesis of prostaglandin analogs, such as bimatoprost. Prostaglandin analogs are used to reduce intraocular pressure in glaucoma and to promote eyelash growth. The compound is a key intermediate for introducing the side chain onto the prostaglandin core structure.
|
|---|---|
| ln Vitro |
In vitro activity is not measured for HYDRIDE-L as it is a synthetic intermediate. Its utility is demonstrated through successful conversion to prostaglandin analogs. The compound's chemical reactivity and stability under various reaction conditions are characterized in vitro.
|
| ln Vivo |
In vivo activity is not applicable to HYDRIDE-L. The compound is a chemical intermediate used in the synthesis of prostaglandin analogs, which are pharmacologically active. The intermediate itself is not administered in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to HYDRIDE-L. Standard characterization includes NMR spectroscopy (¹H, ¹³C) to confirm structure, HPLC to assess purity, and mass spectrometry for molecular weight confirmation. The compound is typically evaluated for its suitability as a synthetic building block.
|
| Cell Assay |
In vitro cellular assays are not performed on HYDRIDE-L. The compound is used as a chemical reagent in organic synthesis rather than a biological test agent. Its primary evaluation involves chemical properties such as solubility in organic solvents and stability under storage conditions.
|
| Animal Protocol |
In vivo animal studies are not conducted on HYDRIDE-L. The compound is a synthetic intermediate used in the chemical synthesis of prostaglandin analogs. Animal efficacy and toxicity studies are performed on the final prostaglandin products.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies are not performed on HYDRIDE-L. The compound is a chemical intermediate and not a drug candidate. Its physicochemical properties, such as solubility and stability, are characterized for synthetic applications.
|
| Toxicity/Toxicokinetics |
Toxicological studies are not conducted on HYDRIDE-L. The compound is handled as a chemical reagent with standard laboratory precautions. Its safety data sheet indicates it is for research use only.
|
| Additional Infomation |
HYDRIDE-L (CAS 41639-74-1) is a prostaglandin analog intermediate, also known as (+)-(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one. It is used in the synthesis of prostaglandin analogs such as bimatoprost. The compound has a molecular formula of C₁₈H₂₂O₄ and a molecular weight of 302.36. This product is for research use only.
|
| Molecular Formula |
C18H22O4
|
|---|---|
| Molecular Weight |
302.364885807037
|
| Exact Mass |
302.151
|
| CAS # |
41639-74-1
|
| PubChem CID |
13046417
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
509.2±50.0 °C at 760 mmHg
|
| Flash Point |
185.6±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
0.62
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
413
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1C(C[C@H]2[C@@H]1C[C@H]([C@@H]2/C=C/[C@H](CCC1C=CC=CC=1)O)O)=O
|
| InChi Key |
PFIFPUGALHSEKD-RKCGEVCRSA-N
|
| InChi Code |
InChI=1S/C18H22O4/c19-13(7-6-12-4-2-1-3-5-12)8-9-14-15-10-18(21)22-17(15)11-16(14)20/h1-5,8-9,13-17,19-20H,6-7,10-11H2/b9-8+/t13-,14+,15+,16+,17-/m0/s1
|
| Chemical Name |
(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3073 mL | 16.5366 mL | 33.0732 mL | |
| 5 mM | 0.6615 mL | 3.3073 mL | 6.6146 mL | |
| 10 mM | 0.3307 mL | 1.6537 mL | 3.3073 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
